Editas Medicine Inc Stock Price, News & Analysis

Editas Medicine has successfully dosed and achieved neutrophil and platelet engraftment in the first patient in the Phase 1/2 RUBY trial of EDIT-301 for severe sickle cell disease. This marks the first clinical application of the AsCas12a enzyme for human gene editing. The FDA has lifted a partial hold on the trial, allowing the inclusion of efficacy data for future marketing applications. Additional patients are being enrolled across multiple U.S. and Canadian sites, with top-line clinical results expected by year-end 2022.

Editas Medicine (Nasdaq: EDIT) will host a conference call on August 3, 2022, at 8:00 a.m. ET to discuss its Q2 2022 financial results and corporate updates. U.S. callers can join by dialing 1-877-407-0989, while international callers should use +1-201-389-0921. The call will be accessible via a webcast on Editas Medicine's website, with a replay available one hour post-call. Editas focuses on genome editing with CRISPR technology, aiming to develop treatments for serious diseases.

Editas Medicine, Inc. (Nasdaq: EDIT) has granted an inducement stock option award to its newly appointed Chief Medical Officer, Dr. Baisong Mei. This option allows Dr. Mei to purchase up to 171,602 shares at a price of $14.99 each, reflecting the closing price on the grant date. The option vests over four years, with 25% vesting after the first year and the remainder monthly, contingent on Dr. Mei's continued service. Editas focuses on CRISPR/Cas9 and Cas12a technologies to develop genomic treatments for serious diseases.

Editas Medicine announced the appointment of Baisong Mei, M.D., Ph.D., as Senior Vice President and Chief Medical Officer. Dr. Mei will spearhead clinical research and drug development across various therapeutic areas, including hematology, oncology, and ophthalmology. With over 20 years of experience, he has a strong record in advancing innovative medicines through clinical development and regulatory approval. His leadership is expected to bolster Editas's pipeline and accelerate the delivery of transformative genomic medicines to patients.

Editas Medicine (Nasdaq: EDIT) and Immatics have announced a strategic research collaboration focusing on developing cancer treatments. This partnership aims to integrate Editas's CRISPR gene editing technology with Immatics’ ACTallo® gamma-delta T cell therapies to enhance tumor recognition and destruction. Editas will receive an undisclosed upfront cash payment, additional milestone payments, and royalties on future product sales resulting from this collaboration. This partnership underscores the potential of engineered cell therapies in revolutionizing cancer treatment.

Editas Medicine (Nasdaq: EDIT) announced the grant of stock options to its new President and CEO, Dr. Gilmore O’Neill, as part of his inducement to join the company. Effective June 1, 2022, Dr. O’Neill received an option to purchase 950,209 shares at $11.54 per share, the closing price on the grant date. The options vest over four years, with the first 25% vesting after one year. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to strengthen leadership as Editas continues to advance its genome editing technologies.

Editas Medicine, Inc. (Nasdaq: EDIT) presented data on its innovative SLEEK gene editing technology at the ASGCT Annual Meeting. SLEEK achieves over 90% knock-in efficiency for multiple transgenes in cell types like T cells and NK cells, enhancing tumor clearance in ovarian cancer models. This advancement supports the development of EDIT-202, an iPSC-derived NK cell therapy. Editas also shared findings on its EDIT-101 program for retinal degeneration and will present on EDIT-103, showcasing nearly 100% gene editing success in primate studies.

Editas Medicine announced that the FDA granted Orphan Drug Designation to EDIT-301 for treating beta thalassemia. This investigational gene editing medicine is pivotal in addressing the urgent need for treatment options for patients suffering from this severe disease. The company is on track to dose its first patient by year-end 2022 and has also received Rare Pediatric Disease designation for the treatment of both beta thalassemia and sickle cell disease. EDIT-301 aims to provide a one-time, durable treatment benefit and is currently in a clinical study for sickle cell disease.

Editas Medicine announced promising preclinical results for EDIT-103, targeting rhodopsin-associated retinitis pigmentosa (RHO-adRP). In non-human primates, nearly 100% gene editing knockout of the RHO gene was achieved, with over 30% normal protein replacement levels. The data indicates potential for photoreceptor preservation and functionality restoration. The company expects to initiate IND-enabling studies by the end of 2022, advancing towards clinical application of this mutation-independent CRISPR/Cas9-based therapy.